Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject (man or woman) is ≥ 18 and ≤ 80 years old.~* Subject is diagnosed with rheumatoid arthritis (RA) as determined by meeting the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism classification criteria for RA.~* Subject has RA duration of at least 3 months.~* Subject has active RA defined as ≥ 6 swollen joints and ≥ 6 tender joints (based on 66/68 joint count excluding distal interphalangeal joints) at screening and baseline and at least 1 of the following at screening:~  * erythrocyte sedimentation rate ≥ 28 mm/hr~ * serum C-reactive protein \> 1.0 mg/dL~* Subject has a positive rheumatoid factor or anti-cyclic citrullinated peptide at screening.~* Subject has taken methotrexate (MTX) for ≥ 12 consecutive weeks and is on a stable dose of oral or subcutaneous MTX 7.5 to 25 mg/week for ≥ 8 weeks before receiving the investigational product and is willing to remain on a stable dose throughout the study.~* For a subject on nonsteroidal anti-inflammatory drugs (NSAIDs) or low potency analgesics such as tramadol, Soma Compounds, Fioricet, or Fiorinal, the dose should be stable for ≥ 2 weeks before screening.~* For a subject on oral corticosteroids (≤ 10 mg prednisone or equivalent), the dose should be stable for ≥ 4 weeks before screening.~* Subject has no known history of active tuberculosis.~* Subject has a negative test for tuberculosis during screening defined as either:~  * negative purified protein derivative (PPD) defined as \< 5 mm of induration at 48 to 72 hours after test is placed OR~ * negative Quantiferon test~* Subject with a positive PPD and a history of Bacillus Calmette-Guérin vaccination is allowed with a negative Quantiferon test.~* Subject with a positive PPD test (without a history of Bacillus Calmette-Guérin vaccination) or a subject with a positive or indeterminate Quantiferon test is allowed if they have all of the following:~  * no symptoms of tuberculosis according to the worksheet provided by the sponsor, Amgen Inc.~ * documented history of adequate prophylaxis initiation before receiving investigational product in accordance with local recommendations~ * no known exposure to a case of active tuberculosis after most recent prophylaxis~Exclusion Criteria:~* Subject has a history of prosthetic or native joint infection.~* Subject has an active infection or history of infections as follows:~  * any active infection for which systemic anti-infectives were used within 28 days before first dose of investigational product~ * a serious infection, defined as requiring hospitalization or intravenous (IV) anti-infective(s) within 8 weeks before the first dose of investigational product~ * recurrent or chronic infections or other active infection that, in the opinion of the investigator, might cause this study to be detrimental to the subject~* Subject has a positive blood test for human immunodeficiency virus (HIV).~* Subject has a positive hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C virus antibody result at screening.~* Subject has uncontrolled, clinically significant systemic disease such as diabetes mellitus, cardiovascular disease including moderate or severe heart failure (New York Heart Association Class III/IV), renal disease, liver disease, or hypertension.~* Subject had a malignancy within 5 years EXCEPT for treated and considered cured cutaneous squamous or basal cell carcinoma, in situ cervical cancer, OR in situ breast ductal carcinoma.~* Subject has a history of neurologic symptoms suggestive of central or peripheral nervous system demyelinating disease.~* Subject has a major chronic inflammatory disease or connective tissue disease other than RA, with the exception of secondary Sjögren's syndrome.~* Subject has a concurrent medical condition that, in the opinion of the investigator, could cause this study to be detrimental to the subject.~* Subject has laboratory abnormalities at screening, including any of the following:~  * hemoglobin \< 9 g/dL~ * platelet count \< 100 000/mm³~ * white blood cell count \< 3 000/mm³~ * aspartate aminotransferase and/or alanine aminotransferase ≥ 2.0 x the upper limit of normal~ * creatinine clearance \< 50 mL/min (Cockroft-Gault formula)~ * any other laboratory abnormality, that, in the opinion of the investigator, will prevent the subject from completing the study or will interfere with the interpretation of the study results.~* Subject has used commercially available or investigational biologic therapies for RA as follows:~  * anakinra, etanercept within 1 month before the first dose of investigational product~ * abatacept, tocilizumab, adalimumab, golimumab, certolizumab within 3 months before the first dose of investigational product~ * other experimental or commercially available biologic therapies for RA within 3 months or 5 half-lives (whichever is longer) before the first dose of investigational product~ * rituximab within 9 months before the investigational product along with evidence of incomplete B cell recovery~* Subject has received live vaccines within 28 days before the first dose of investigational product or plans to receive live vaccines during the course of the study.~* Subject has previously received Remicade® (infliximab) or a biosimilar of infliximab.~* Woman who is pregnant or breast feeding, or plans to become pregnant while enrolled in the study and for 6 months after the last dose of investigational product.~* Women of childbearing potential (ie, neither surgically sterile nor postmenopausal) and do not agree to use adequate contraception (eg, true abstinence, sterilization, birth control pills, Depo-Provera® \[medroxyprogesterone\] injections, or contraceptive implants) while on study and for 6 months after the last dose of investigational product.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ABP 710 (Type: EXPERIMENTAL): Participants randomized to receive a 3 mg/kg intravenous (IV) infusion of ABP 710 on day 1, at weeks 2 and 6, and every 8 weeks thereafter until week 22.~At week 22 participants continued receiving 3 mg/kg ABP 710 every 8 weeks through week 46.
- Infliximab (Type: ACTIVE_COMPARATOR): Participants randomized to receive a 3 mg/kg IV infusion of infliximab on day 1, at weeks 2 and 6, and every 8 weeks thereafter until week 22.~At week 22 participants were re-randomized in a 1:1 ratio to either continue receiving 3 mg/kg infliximab every 8 weeks or transition to receive 3 mg/kg ABP 710 every 8 weeks through week 46.

Based on this trial design, predict the completion outcome and termination type (if applicable).